Botleroo Rinky A, Bhandari Renu, Ahmed Rowan, Kareem Roaa, Gyawali Mallika, Venkatesan Nanditha, Ogeyingbo Opemipo D, Elshaikh Abeer O
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Internal Medicine, Manipal College of Medical Sciences, Pokhara, NPL.
Cureus. 2021 Aug 9;13(8):e17022. doi: 10.7759/cureus.17022. eCollection 2021 Aug.
Myocardial infarction is one of the leading causes of death worldwide. Poor functional recovery of the myocardium is noticed after an event of myocardial infarction. Researchers and clinicians around the world have been engaged to regenerate the damaged human heart for a long time. Stem cell therapy is an exciting newer therapy to treat cardiovascular diseases. Various types of stem cells have been used to revive the damaged myocardium after myocardial infarction, and they have overall demonstrated safety and moderate efficacy. The specific mechanisms by which these cells help in improving cardiac function are still not completely known. There is growing evidence that intracoronary bone marrow cell transplantation in patients with myocardial infarction beneficially affects the remodeling of the damaged myocardium. Our systematic review article aims to assess the effects and the future of stem cell therapy in patients with myocardial Infarction. We searched articles in PubMed, ScienceDirect, and Google Scholar. Thirty-one studies that included 2171 patients in total were analyzed. Most of these studies showed stem cell therapy is safe and well tolerated in patients, and modest improvements are seen in left ventricular functions with no major adverse effects. However, some studies showed no positive and clinically significant outcomes. So, more high-quality studies on a larger scale are required to support and confirm its efficacy in remodeling damaged myocardium after myocardial infarction. We should also perform studies to determine the timing of cell delivery that is best suited for stem cell therapy.
心肌梗死是全球主要死因之一。心肌梗死后会出现心肌功能恢复不佳的情况。长期以来，世界各地的研究人员和临床医生一直致力于使受损的人类心脏再生。干细胞疗法是一种用于治疗心血管疾病的令人兴奋的新型疗法。多种类型的干细胞已被用于在心肌梗死后使受损心肌恢复生机，总体上已证明其安全性和一定疗效。这些细胞帮助改善心脏功能的具体机制仍不完全清楚。越来越多的证据表明，对心肌梗死患者进行冠状动脉内骨髓细胞移植对受损心肌的重塑有有益影响。我们的系统评价文章旨在评估干细胞疗法对心肌梗死患者的疗效及未来发展。我们在PubMed、ScienceDirect和谷歌学术上搜索了相关文章。共分析了31项研究，总计纳入2171名患者。这些研究大多表明干细胞疗法在患者中是安全且耐受性良好的，左心室功能有适度改善且无重大不良反应。然而，一些研究未显示出积极且具有临床意义的结果。因此，需要更多大规模的高质量研究来支持和证实其在心肌梗死后重塑受损心肌方面的疗效。我们还应开展研究以确定最适合干细胞疗法的细胞递送时机。
